List of Excipients in Branded Drug LITHIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Precision Dose Inc	LITHIUM	lithium	68094-757	ANHYDROUS CITRIC ACID
Precision Dose Inc	LITHIUM	lithium	68094-757	RASPBERRY
Precision Dose Inc	LITHIUM	lithium	68094-757	SODIUM BENZOATE

Generic Drugs Containing LITHIUM

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	GLYCERIN
PAI Holdings LLC dba PAI Pharma	lithium	0121-1027	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in LITHIUM?

# Of NDCs	Excipient
4	ALCOHOL
2	ANHYDROUS CITRIC ACID
4	CITRIC ACID MONOHYDRATE

Lithium Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Lithium is an established, low-cost, narrow-therapeutic-index medicine with limited molecule-level patent protection. Commercial opportunity is concentrated in formulation performance, dosing convenience, pediatric and geriatric usability, taste masking, supply reliability, and regulatory execution rather than in new chemical entity exclusivity.

The main products are lithium carbonate immediate-release tablets and capsules, lithium carbonate extended-release tablets, and lithium citrate oral solutions. Lithium carbonate products are generally dosed in milligrams, while lithium citrate products are often labeled in milliequivalents. The conversion between products is not automatically one-to-one from a clinical or pharmacokinetic perspective because formulation, salt, release rate, food effect, and gastrointestinal transit can affect lithium exposure (FDA, 2024a).

What pharmaceutical formulations contain lithium?

Lithium is marketed primarily as lithium carbonate or lithium citrate.

Product type	Typical dosage form	Primary commercial use	Excipient strategy
Lithium carbonate immediate release	Tablet or capsule	Flexible dose titration and lower manufacturing cost	Rapid disintegration, content uniformity, low-cost direct compression or wet granulation
Lithium carbonate extended release	Matrix or modified-release tablet	Reduced dosing frequency and smoother exposure	Release-control polymer, robust tablet matrix, reduced dose dumping risk
Lithium citrate oral solution	Oral solution or syrup	Patients unable to swallow tablets, pediatric and geriatric use	Taste masking, viscosity control, microbial protection, dose-measuring accuracy
Compounded liquid	Extemporaneous oral liquid	Institutional and specialized patient populations	Stability, preservative control, standardized concentration
Specialty multiparticulate formulation	Granules, pellets, or sprinkle dosage form	Dysphagia and controlled administration	Multiparticulate release control, taste masking, capsule or sachet delivery

Lithium carbonate contains approximately 27.3% elemental lithium by weight. Lithium citrate products are commonly labeled by lithium-ion equivalence, often 8 mEq per 5 mL, but the exact concentration depends on the product. Product labeling must control the relationship between salt strength, lithium-ion content, and dosing volume.

What excipients are used in lithium products?

Lithium product labels typically use conventional oral solid and liquid excipients. The exact composition varies by manufacturer and dosage form.

Immediate-release tablets and capsules

Common excipient categories include:

• Microcrystalline cellulose or other diluents
• Lactose or alternative fillers
• Povidone or another binder
• Croscarmellose sodium or sodium starch glycolate as a disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Film-coating polymers, plasticizers, pigments, and opacifiers

The primary technical challenge is not chemical stabilization of lithium carbonate. It is achieving reliable dose uniformity and disintegration at a low active-drug loading relative to the total tablet mass. Lubricant level and blending time require control because over-lubrication can slow dissolution and increase batch variability.

Extended-release tablets

Extended-release lithium tablets may use:

• Hydrophilic matrix polymers such as hypromellose
• Hydrophobic release retardants
• Granulation binders
• Pore-forming agents
• Film-coating systems
• Tablet-strength enhancers

The excipient system must prevent rapid lithium release under altered pH, high ionic strength, mechanical stress, and alcohol exposure where relevant. A formulation that passes standard dissolution testing but releases lithium rapidly after crushing, chewing, or exposure to alcohol has a material safety problem.

Oral solutions

Lithium citrate oral solutions typically require:

• Purified water
• Sweeteners such as sucrose or non-sucrose alternatives
• Flavor systems
• pH adjusters and buffers
• Viscosity modifiers
• Preservatives where justified
• Chelating or stabilizing agents where compatible
• Colorants, if used

Taste masking is commercially important because lithium salts can produce a salty, metallic, or otherwise unpleasant taste. The formulation must retain dose accuracy after storage, shaking, repeated opening, and use with oral syringes.

How should an excipient strategy address lithium’s narrow therapeutic index?

Lithium has a narrow therapeutic window. Small changes in exposure can produce toxicity, while insufficient exposure can reduce clinical effectiveness. The excipient strategy should therefore prioritize pharmacokinetic reproducibility over tablet aesthetics or maximum drug loading.

Key development controls include:

1. Consistent dissolution. Immediate-release and extended-release products should maintain tight dissolution profiles across batches and relevant pH conditions.
2. Low variability in absorption. Changes in particle size, granulation, porosity, polymer grade, and lubricant concentration can affect release and absorption.
3. Robustness to administration errors. Extended-release tablets should resist unintended crushing and rapid release.
4. Food-effect evaluation. Formulation changes should assess fed and fasted performance, particularly where the product is intended to be taken consistently with or without food.
5. Container-closure control. Liquid products require protection against evaporation, microbial contamination, dose-volume drift, and interaction with dispensing devices.
6. Dose-measuring accuracy. Oral solutions should support calibrated oral syringes rather than relying solely on household spoons.
7. Interchangeability control. Immediate-release, extended-release, tablet, capsule, and liquid products should not be treated as automatically interchangeable.

A formulation change that alters exposure may trigger a regulatory burden disproportionate to the low cost of the active ingredient. FDA treats lithium as a narrow-therapeutic-index drug for which bioequivalence and product quality require particular attention (FDA, 2024b).

What FDA regulatory pathways apply to lithium products?

Most conventional lithium products are candidates for an abbreviated new drug application rather than a new drug application.

Development objective	Likely pathway	Main regulatory issue
Generic immediate-release lithium carbonate	ANDA under section 505(j)	Pharmaceutical equivalence and bioequivalence
Generic extended-release lithium carbonate	ANDA	Release-profile similarity, pharmacokinetics, and potential food-effect requirements
New liquid, sprinkle, or modified-release product	505(b)(2) NDA	Bridging to listed drug and justification for formulation differences
New indication or materially different clinical use	NDA or 505(b)(2)	Clinical and labeling evidence
Compounded preparation	State and federal compounding framework	Not equivalent to FDA-approved commercial product

FDA’s product-specific guidance and Orange Book listings determine the reference product, dosage form, strength, and relevant bioequivalence approach. For an extended-release lithium product, formulation sameness alone is unlikely to establish substitutability without appropriate pharmacokinetic and dissolution data (FDA, 2024a; FDA, 2024b).

What is the Orange Book status of lithium?

Lithium carbonate and lithium citrate are established prescription drug substances with extensive generic competition. The principal commercial barrier is regulatory and technical execution, not an active compound patent.

The Orange Book should be reviewed by:

• Active ingredient and salt
• Dosage form
• Strength
• Immediate-release versus extended-release status
• Reference-listed drug designation
• Listed patents and exclusivity
• Therapeutic-equivalence code
• Current marketing status

A product sponsor should not assume that a formulation patent covering one extended-release product also blocks all lithium carbonate products. Patent scope depends on the claims, listed product, dosage form, and infringement theory.

Patent and exclusivity position

Asset category	Current strategic relevance
Lithium carbonate compound claims	Generally expired or commercially irrelevant
Lithium citrate compound claims	Generally expired or commercially irrelevant
Conventional immediate-release formulations	Low patent differentiation
Extended-release matrices	Potential formulation differentiation, but crowded prior art
Taste-masked liquids	Potentially protectable through composition and use claims
Unit-dose packaging and dispensing systems	Possible device or packaging claims
Pediatric sprinkle or multiparticulate products	Potential formulation and method-of-use value
Manufacturing process improvements	Potential trade-secret or process-patent value

No meaningful new chemical entity exclusivity remains for standard lithium therapy. Commercial diligence should focus on active Orange Book listings, current claims, prosecution history, and litigation records rather than historical brand patents.

When does lithium lose exclusivity?

Lithium’s core exclusivity has already expired. Generic manufacturers can compete in standard immediate-release and extended-release categories if they satisfy FDA approval requirements.

There is no single “lithium patent expiration date” because the relevant date depends on the specific product, formulation, manufacturer, and listed patent. The commercial timeline is better described as follows:

Milestone	Commercial effect
Original lithium approval	Historical originator exclusivity
Expiration of compound protection	Entry of conventional generics
Expiration of product-specific formulation patents	Reduced barrier for equivalent modified-release products
FDA approval of competing ANDAs	Substitution and price pressure
Launch of differentiated liquid or multiparticulate product	Potential premium segment
Loss of manufacturing exclusivity or supply contract	Opportunity for second-source suppliers

What generic entry risks exist for lithium?

Generic entry risk is high in standard dosage forms and moderate in differentiated delivery systems.

Immediate-release products

Immediate-release lithium carbonate tablets and capsules are vulnerable to:

• Multiple ANDA filings
• Price competition
• Pharmacy substitution
• Hospital purchasing pressure
• Contract manufacturing
• Private-label launches

Excipient differentiation alone is unlikely to support a durable premium unless it produces measurable improvements in dissolution, tolerability, stability, swallowing, or adherence.

Extended-release products

Extended-release products have greater technical barriers because sponsors must manage:

• Release kinetics
• Dose dumping
• Tablet integrity
• Food effects
• Crushing and chewing risk
• In vitro-in vivo correlation
• Bioequivalence variability

These barriers can support a more defensible commercial position, but they do not create durable exclusivity without valid claims, regulatory differentiation, or supply advantages.

Liquid products

Liquid lithium has a more attractive niche opportunity. Many patients cannot swallow tablets, and oral solutions are useful in pediatric, geriatric, psychiatric-inpatient, and medically complex populations. Commercial risks include:

• Poor taste
• Dosing errors
• Shorter shelf life
• Microbial contamination
• Packaging incompatibility
• Limited pharmacy inventory
• Concentration confusion between products

A high-quality oral solution can compete on usability and reliability even when the active ingredient is generic.

What formulation patents could protect lithium products?

The strongest potential claims would usually cover a defined product architecture rather than the lithium molecule.

Extended-release formulation claims

Potential claim elements include:

• Lithium carbonate particle-size distribution
• Defined polymer grades and concentration ranges
• Specific matrix composition
• Release profile at multiple pH values
• Resistance to alcohol-induced dose dumping
• Crushing-resistant dosage form
• Defined fed-to-fasted pharmacokinetic relationship

Liquid formulation claims

Potential claim elements include:

• Lithium citrate concentration
• Buffer system
• Sweetener and flavor combination
• Preservative system
• Defined pH range
• Long-term and in-use stability
• Low-sedimentation or no-shake performance
• Compatibility with oral syringes

Pediatric and dysphagia products

Potential claims could cover:

• Taste-masked granules
• Sprinkle capsules
• Unit-dose sachets
• Multiparticulate modified release
• Administration with soft food
• Child-resistant packaging
• Dose-calibrated dispensing systems

Patent strength depends on claim breadth, enablement, written description, prior art, and the ability to demonstrate a clinically relevant advantage. A narrow excipient substitution with no measurable product benefit is unlikely to support a strong commercial position.

How strong is the lithium patent estate?

The lithium patent estate is weak for the active ingredient and conventional products, but it can be moderate for carefully engineered delivery systems.

Patent layer	Strength	Reason
Active ingredient	Low	Long-established salts and broad prior art
Immediate-release tablet	Low	Mature technology and many generic alternatives
Extended-release tablet	Low to moderate	Technical barriers exist, but prior art is extensive
Taste-masked liquid	Moderate	Formulation and sensory-performance claims may differentiate
Pediatric multiparticulate	Moderate	Fewer direct substitutes and higher development complexity
Packaging and dispensing	Low to moderate	Useful commercially but easy to design around
Manufacturing process	Moderate as trade secret	Process know-how can protect consistency without public disclosure

Trade-secret protection may be more valuable than patents for particle engineering, granulation parameters, coating conditions, and process controls. Trade secrets do not prevent independent development, but they can protect manufacturing advantages when reverse engineering is difficult.

Which companies are positioned to compete in lithium?

The competitive landscape includes:

• Generic pharmaceutical manufacturers selling lithium carbonate tablets, capsules, and extended-release tablets
• Specialty manufacturers supplying oral solutions
• Contract development and manufacturing organizations
• Hospital-compounding pharmacies
• Drug-delivery companies developing multiparticulate or taste-masked systems
• Packaging suppliers providing oral syringes, unit-dose cups, and child-resistant systems

The most defensible commercial position is likely to come from a combined product-and-service model: a differentiated dosage form, validated dispensing device, reliable supply, and clinical support for dose conversion and monitoring.

Public-company revenue exposure is difficult to isolate because lithium sales are often included in broad generic portfolios. Standard lithium products are usually low-revenue-per-unit products with limited pricing power. A differentiated product can improve gross margin, but market size is constrained by the established generic base and the relatively small number of patients requiring a specific delivery format.

What licensing deals are commercially plausible for lithium?

Licensing opportunities are more likely to involve technology than the lithium active ingredient.

Potential deal structures include:

1. Platform license. A delivery company licenses taste masking, multiparticulate release, or abuse-resistant technology.
2. Regional commercialization license. A specialty pharmaceutical company receives rights to sell an oral solution or modified-release product in selected markets.
3. Manufacturing license. A manufacturer licenses a process for high-uniformity lithium tablets or stable liquid production.
4. Device combination license. A sponsor licenses a calibrated dispenser, unit-dose package, or adherence system.
5. Supply agreement. A generic company secures dual-source lithium carbonate, lithium citrate, or critical excipients.

A license is more attractive when it includes regulatory data, validated manufacturing, freedom-to-operate analysis, and a differentiated label. A formulation patent without manufacturing capacity or FDA approval is less valuable.

What manufacturing and excipient supply barriers affect lithium?

Lithium products use generally available excipients, so raw-material scarcity is not normally the principal barrier. The relevant risks are quality consistency and process control.

Important supply-chain controls include:

• Excipient particle-size consistency
• Low variability in polymer viscosity grades
• Reliable pharmaceutical-grade lithium carbonate or lithium citrate
• Control of elemental impurities
• Compatibility between liquid formulation and packaging
• Availability of validated coating and granulation capacity
• Backup sources for flavors, preservatives, and oral syringes

For a liquid product, excipient suppliers should provide robust documentation for microbial limits, preservative quality, elemental impurities, and extractables and leachables. For modified-release tablets, polymer lot variability can shift dissolution and create batch-release failures.

What commercial opportunities exist beyond standard lithium tablets?

The strongest opportunities are product segments where usability or supply reliability matters.

1. Taste-masked oral solution

A stable, palatable solution with a calibrated oral syringe can target pediatric, geriatric, dysphagia, and inpatient use. The product should minimize dosing-volume confusion and support consistent administration.

2. Pediatric multiparticulate dosage form

A sprinkle or granule product could address patients who cannot swallow tablets. The formulation must preserve dose uniformity when mixed with soft food and prevent rapid lithium release.

3. Lower-frequency extended release

A robust once-daily or simplified dosing product could compete on adherence, provided exposure is clinically appropriate and bioequivalence or clinical bridging is established.

4. Unit-dose institutional packaging

Premeasured oral solution cups or sachets could reduce medication errors in hospitals, residential treatment facilities, and correctional-health systems.

5. Supply-secure generic platform

A manufacturer with dual-source active pharmaceutical ingredient and excipient supply may win contracts even without patent differentiation. Lithium shortages or recalls can shift purchasing toward reliable suppliers.

6. Digital dispensing and adherence support

A connected oral dispenser or dose-tracking package could add value, but the system would need to comply with combination-product, device, privacy, and clinical-support requirements.

How does lithium compare with competing mood-stabilizer products?

Lithium competes clinically with anticonvulsant and antipsychotic therapies, but its formulation economics differ.

Product category	Formulation opportunity	Generic pressure	Excipient value
Lithium carbonate IR	Limited	High	Low
Lithium carbonate ER	Moderate	High to moderate	Moderate
Lithium citrate solution	High	Moderate	High
Lamotrigine	Orally disintegrating and chewable forms	High	Moderate
Valproate	Liquid, sprinkle, ER products	High	Moderate
Carbamazepine	Suspension and ER products	High	Moderate
Atypical antipsychotics	Long-acting injectables and specialty delivery	Variable	Lower for excipient-only strategies

Lithium’s monitoring burden increases the value of predictable dosing and clear administration instructions. It also limits the commercial attractiveness of products that introduce unnecessary formulation complexity without a measurable clinical or operational benefit.

What litigation and Paragraph IV risks affect lithium?

Paragraph IV risk is concentrated in product-specific formulation and method claims rather than in lithium’s active ingredient. A generic sponsor challenging a listed patent would typically assess:

• Non-infringement of formulation claims
• Invalidity based on prior art
• Obviousness of excipient combinations
• Lack of enablement
• Inadequate written description
• Absence of clinically meaningful distinction
• Design-around options using different polymers or processing conditions

For standard lithium products, litigation risk is generally lower than for recently approved specialty drugs because the underlying technology is mature. For a new 505(b)(2) product, a sponsor could face litigation if the reference product has listed patents or if the new formulation relies on protected delivery technology.

Settlement agreements should be reviewed for launch dates, licenses, authorized-generic rights, supply obligations, restrictions on product design, and geographic scope. No commercial decision should rely only on a patent expiration date without reviewing the full Orange Book listing and litigation record.

What is the best excipient strategy for a new lithium product?

The strongest strategy is to select a patient problem first and design the excipient system around a measurable product advantage.

Target product	Preferred excipient objective	Commercial proof point
Immediate-release tablet	Dose uniformity and rapid, reproducible disintegration	Tight dissolution and low batch variability
Extended-release tablet	Controlled release with dose-dumping resistance	Defined dissolution and pharmacokinetic profile
Oral solution	Taste masking and dose accuracy	Acceptability testing and calibrated dosing
Pediatric granules	Palatability and soft-food compatibility	Uniform delivery after mixing
Institutional unit dose	Stability and dispensing control	Lower administration error rate
Supply-secure generic	Process robustness and dual sourcing	Reliable batch release and continuity of supply

The highest-value excipient work is likely to be in oral liquids and pediatric or dysphagia products. Conventional tablet excipient optimization can reduce manufacturing cost and variability, but it is less likely to support pricing power.

Key Takeaways

• Lithium’s active-ingredient patent protection is no longer the commercial driver.
• Immediate-release lithium carbonate is a highly competitive generic market.
• Extended-release products have greater technical and regulatory barriers but remain exposed to generic competition.
• Lithium citrate oral solution offers the clearest excipient-led opportunity.
• Taste masking, dose-measuring accuracy, stability, and packaging compatibility are central development priorities.
• Pediatric multiparticulates, sprinkle products, and unit-dose liquids can support meaningful differentiation.
• Excipient substitutions should be tied to measurable dissolution, pharmacokinetic, stability, palatability, or administration benefits.
• Manufacturing know-how and supply reliability may provide more practical protection than broad formulation patents.
• Paragraph IV risk is product-specific and depends on listed formulation patents, not on lithium as a molecule.
• A commercially credible lithium program requires an FDA pathway, bioequivalence strategy, Orange Book review, formulation freedom-to-operate analysis, and reliable supply chain.

FAQs

Can lithium carbonate be formulated as a liquid?

Yes. Lithium citrate is commonly used for oral liquid formulations because it can provide a stable, measurable lithium-ion concentration. The product must control taste, pH, microbial quality, sedimentation, packaging compatibility, and dose-volume accuracy.

Which excipients are most important for lithium oral solution development?

The highest-impact categories are sweeteners, flavors, buffers, viscosity modifiers, preservatives, and container-closure materials. Their value depends on palatability, chemical and microbiological stability, and accurate dosing during repeated use.

Is extended-release lithium protected by strong patents?

The active ingredient is not strongly protected. Individual extended-release products may have formulation patents, but the estate is generally narrower and more vulnerable to design-around strategies than patents covering newer molecular entities.

Does a lithium liquid require a new drug application?

Not always. A generic liquid may qualify for an ANDA if it can reference an appropriate listed drug and meet FDA requirements. A materially different concentration, formulation, delivery system, or clinical use may require a 505(b)(2) NDA.

What is the most attractive lithium formulation opportunity?

A palatable, stable, accurately measured lithium citrate oral solution or pediatric multiparticulate product offers the strongest combination of patient need, excipient differentiation, and commercial defensibility.

References

1. U.S. Food and Drug Administration. (2024a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration. (2024b). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development
3. U.S. Food and Drug Administration. (2015). MAPP 5015.1: Regulatory classification of pharmaceutical co-crystals. https://www.fda.gov/
4. National Library of Medicine. (2024). Lithium carbonate drug labels. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
5. National Library of Medicine. (2024). Lithium citrate oral solution drug labels. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
6. U.S. Food and Drug Administration. (2018). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://www.fda.gov/
7. U.S. Food and Drug Administration. (2016). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. https://www.fda.gov/